Free Trial

Connect Biopharma (CNTB) Stock Price, News & Analysis

Connect Biopharma logo
$1.04 +0.06 (+5.82%)
As of 10:03 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Connect Biopharma Stock (NASDAQ:CNTB)

Key Stats

Today's Range
$1.05
$1.07
50-Day Range
$0.68
$1.08
52-Week Range
$0.51
$1.60
Volume
5,222 shs
Average Volume
55,941 shs
Market Capitalization
$57.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
Consensus Rating
Buy

Company Overview

Connect Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
76th Percentile Overall Score

CNTB MarketRank™: 

Connect Biopharma scored higher than 76% of companies evaluated by MarketBeat, and ranked 257th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Connect Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Connect Biopharma has only been the subject of 1 research reports in the past 90 days.

  • Read more about Connect Biopharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Connect Biopharma are expected to decrease in the coming year, from ($0.22) to ($0.32) per share.

  • Price to Book Value per Share Ratio

    Connect Biopharma has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Connect Biopharma's valuation and earnings.
  • Percentage of Shares Shorted

    0.04% of the float of Connect Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Connect Biopharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Connect Biopharma has recently decreased by 72.15%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Connect Biopharma does not currently pay a dividend.

  • Dividend Growth

    Connect Biopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.04% of the float of Connect Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Connect Biopharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Connect Biopharma has recently decreased by 72.15%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Connect Biopharma has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Connect Biopharma this week, compared to 0 articles on an average week.
  • Search Interest

    5 people have searched for CNTB on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Connect Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Connect Biopharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    22.60% of the stock of Connect Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    58.72% of the stock of Connect Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Connect Biopharma's insider trading history.
Receive CNTB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Connect Biopharma and its competitors with MarketBeat's FREE daily newsletter.

CNTB Stock News Headlines

White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
See More Headlines

CNTB Stock Analysis - Frequently Asked Questions

Connect Biopharma's stock was trading at $1.38 at the start of the year. Since then, CNTB stock has decreased by 23.2% and is now trading at $1.06.
View the best growth stocks for 2025 here
.

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) issued its quarterly earnings data on Thursday, May, 15th. The company reported ($0.19) earnings per share for the quarter, beating analysts' consensus estimates of ($0.26) by $0.07.

Connect Biopharma (CNTB) raised $150 million in an IPO on Friday, March 19th 2021. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. Jefferies, VB Leerink, Piper Sandler and CICC served as the underwriters for the IPO.

Shares of CNTB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Connect Biopharma investors own include NVIDIA (NVDA), Adobe (ADBE), Broadcom (AVGO), Arista Networks (ANET), ServiceNow (NOW), Builders FirstSource (BLDR) and CymaBay Therapeutics (CBAY).

Company Calendar

Last Earnings
5/15/2025
Today
7/01/2025
Next Earnings (Estimated)
9/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CNTB
Employees
110
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$7.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+560.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$26.03 million
Price / Cash Flow
N/A
Book Value
$1.67 per share
Price / Book
0.63

Miscellaneous

Free Float
43,004,000
Market Cap
$58.89 million
Optionable
Optionable
Beta
-0.20
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:CNTB) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners